应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06990 科伦博泰生物
已收盘 11-11 16:08:05
459.200
-4.600
-0.99%
最高
466.000
最低
449.400
成交量
53.09万
今开
465.800
昨收
463.800
日振幅
3.58%
总市值
1,097亿
流通市值
812.78亿
总股本
2.39亿
成交额
2.41亿
换手率
0.30%
流通股本
1.77亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读｜科伦博泰生物盘中下跌3.02%，缺乏新增催化下跟随生物科技板块走弱
行情直击 · 10:58
异动解读｜科伦博泰生物盘中下跌3.02%，缺乏新增催化下跟随生物科技板块走弱
生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
金吾财讯 · 11-09 10:08
生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
异动解读｜科伦博泰生物盘中下跌3.07%，12亿元结构性存款认购后股价回吐
行情直击 · 11-06
异动解读｜科伦博泰生物盘中下跌3.07%，12亿元结构性存款认购后股价回吐
科伦博泰生物(06990)盘中涨超7% 认购12亿元结构性存款
财中社 · 11-05
科伦博泰生物(06990)盘中涨超7% 认购12亿元结构性存款
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
智通财经 · 11-05
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
异动解读｜科伦博泰生物盘中上涨3.16%，12亿元结构性存款认购落地
行情直击 · 11-05
异动解读｜科伦博泰生物盘中上涨3.16%，12亿元结构性存款认购落地
科伦博泰生物(06990.HK)认购5亿元浙商银行结构性存款及7亿元中国银行结构性存款
智通财经 · 11-04
科伦博泰生物(06990.HK)认购5亿元浙商银行结构性存款及7亿元中国银行结构性存款
科伦博泰生物(06990)认购总额12亿元银行结构性存款 涉两笔须予披露交易
公告速递 · 11-04
科伦博泰生物(06990)认购总额12亿元银行结构性存款 涉两笔须予披露交易
科伦博泰生物更新2026年10月股份变动月报表，股本维持稳定
公告速递 · 11-04
科伦博泰生物更新2026年10月股份变动月报表，股本维持稳定
CXO板块逆市走强 百济神州（06160）涨5.14%、凯莱英（06821）涨4.19%
金吾财讯 · 11-04
CXO板块逆市走强 百济神州（06160）涨5.14%、凯莱英（06821）涨4.19%
异动解读｜科伦博泰生物盘中上涨3.59%，创新药临床与申报进展持续提供支撑
行情直击 · 11-04
异动解读｜科伦博泰生物盘中上涨3.59%，创新药临床与申报进展持续提供支撑
异动解读｜科伦博泰生物盘中下跌6.11%，实控人连续减持压制股价
行情直击 · 11-03
异动解读｜科伦博泰生物盘中下跌6.11%，实控人连续减持压制股价
【券商聚焦】中信证券：国内医药板块业绩持续修复
金吾财讯 · 11-02
【券商聚焦】中信证券：国内医药板块业绩持续修复
天风 · 11月金股
天风研究 · 11-02
天风 · 11月金股
科伦博泰生物：刘革新减持，好仓比例降至48.73%
港股披露 · 10-30
科伦博泰生物：刘革新减持，好仓比例降至48.73%
科伦博泰生物：刘革新减持，好仓比例降至48.79%
港股披露 · 10-30
科伦博泰生物：刘革新减持，好仓比例降至48.79%
科伦博泰生物：刘革新减持，好仓比例降至48.86%
港股披露 · 10-30
科伦博泰生物：刘革新减持，好仓比例降至48.86%
科伦博泰生物：刘革新减持，好仓比例降至48.65%
港股披露 · 10-30
科伦博泰生物：刘革新减持，好仓比例降至48.65%
科伦博泰生物：刘革新减持，好仓比例降至48.68%
港股披露 · 10-30
科伦博泰生物：刘革新减持，好仓比例降至48.68%
异动解读｜科伦博泰生物盘中上涨3.37%，sac-TMT三项III期研究入选LBA提振预期
行情直击 · 10-29
异动解读｜科伦博泰生物盘中上涨3.37%，sac-TMT三项III期研究入选LBA提振预期
加载更多
公司概况
公司名称：
科伦博泰生物
所属市场：
SEHK
上市日期：
--
主营业务：
四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。
发行价格：
--
{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":459.2,"timestamp":1794384485009,"preClose":463.8,"halted":0,"volume":530857,"delay":0,"changeRate":-0.009918068132815918,"floatShares":177000000,"shares":239000000,"eps":-1.65683,"marketStatus":"已收盘","change":-4.6,"latestTime":"11-11 16:08:05","open":465.8,"high":466,"low":449.4,"amount":240761700,"amplitude":0.035791,"askPrice":459.2,"askSize":300,"bidPrice":458.8,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.748354,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794447000000},"marketStatusCode":5,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":463.8,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.607949,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SKB.HK","impliedVol":0.4852,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1195829500","title":"异动解读｜科伦博泰生物盘中下跌3.02%，缺乏新增催化下跟随生物科技板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1195829500","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195829500?lang=zh_cn&edition=full","pubTime":"2026-11-11 10:58","pubTimestamp":1794365931,"startTime":"0","endTime":"0","summary":"11月11日，科伦博泰生物盘中下跌3.02%，报449.8港元，成交额1.41亿港元。近阶段公司公开消息主要集中于11月4日以闲置自有资金认购合计12亿元保本浮动收益型银行结构性存款，以及此前核心产品sac-TMT新增适应症上市申请获受理。但上述信息均非当日新增催化，对本次股价异动解释力有限。从板块表现看，生物科技板块当日整体偏弱，信达生物跌3.45%，三生制药跌2.84%，康方生物跌2.24%，百济神州跌1.27%，麦科医药-B跌4.41%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"科伦博泰生物走弱，生物科技板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682820601","title":"生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2682820601","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682820601?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:08","pubTimestamp":1794190084,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，截至发稿，再鼎医药 涨13.07%，康诺亚-B涨7.22%，康方生物涨6.33%，科伦博泰生物涨5.36%，药明生物涨4.96%，金斯瑞生物科技涨4.48%，复宏汉霖涨4.04%。2026年上半年，全球生物科技融资、License交易、并购交易金额分别达到502亿美元、1667亿美元和960亿美元，均显著超越去年上半年，医药融资及License交易持续回暖，为医药研发提供了资金支持。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002562.SGD","BK1588","LU0359201612.USD","LU1242518931.SGD","LU0051755006.USD","MEDX","09688","LU0320764243.SGD","BK4581","LU1242518857.USD","159938","HK0000165453.HKD","LU0181495838.USD","LU0348784397.USD","06990","LU0029874061.USD","IBBQ","LU1794554557.SGD","02162","159992","LU2039709279.SGD","ZLAB","09939","LU2476274308.USD","06978","01548","02696","LNGR","CXO","LU0348767384.USD","399441","LU0348825331.USD","BK1610","LU0543330566.HKD","09926","KURE","BK4588","LU0561508036.HKD","XBI","161726","LU0516423091.SGD","LU0196878994.USD","BK1574","LU0456827905.SGD","WX","LU0140636845.USD","02269","LU0456846285.SGD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187860083","title":"异动解读｜科伦博泰生物盘中下跌3.07%，12亿元结构性存款认购后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1187860083","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187860083?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:43","pubTimestamp":1793929412,"startTime":"0","endTime":"0","summary":"11月6日，科伦博泰生物盘中下跌3.07%，报452.6港元，成交额5832.2万港元。消息面上，公司此前公告认购合计12亿元银行结构性存款，市场此前将其解读为账上资金充裕与提升闲置资金使用效率的信号，但该事项本身对主营业务增量有限。具体看，公司分别认购5亿元浙商银行及7亿元中国银行结构性存款，均使用集团闲置自有资金，未动用公开发行或配股所得款项，产品为保本浮动收益型、偏中短期；其中浙商银行产品期限103日，中国银行产品期限185日。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"科伦博泰认购12亿存款，股价回落显谨慎","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681254017","title":"科伦博泰生物(06990)盘中涨超7% 认购12亿元结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2681254017","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681254017?lang=zh_cn&edition=full","pubTime":"2026-11-05 14:21","pubTimestamp":1793859660,"startTime":"0","endTime":"0","summary":"11月5日，药品及生物科技板块盘中走强，科伦博泰生物盘中涨超7%，截至发稿，涨3.35%，报457.20港元，成交额2.61亿港元。同板块宝济药业-B涨33.09%、劲方医药-B涨10.76%、银诺医药-B涨10.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611053923433833.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611053923433833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015969","title":"港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015969?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:47","pubTimestamp":1793846861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股今早继续走高，创新药、CRO概念领衔。中国生物制药11月4日盘后公告，与跨国药企勃林格殷格翰就下一代肿瘤疗法达成重磅对外授权，覆盖6个创新药临床前项目。公司可获3.58亿美元首付款，潜在总额最高达70亿美元，刷新公司BD交易金额纪录。东方证券指出，从医药整体来看，2026年前三季度营收同比增长1.4%，归母净利润同比增长11.6%，扣非归母净利润同比增长18.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU0149534421.HKD","LU0588546209.SGD","HK0000165453.HKD","LU2242644610.SGD","LU2328871848.SGD","LU1770034418.SGD","LU1188198961.HKD","LU2097828631.EUR","LU2097828714.EUR","LU0196878994.USD","LU0463099449.HKD","BK1589","159938","BK4585","LU0607220059.USD","BK1588","LU2097828557.USD","06990","LU0828237510.HKD","BK4588","09939","BK1191","LU1251922891.USD","BK1583","BK1574","BK1521","VXUS","LU1969619763.USD","LU0594300179.USD","LU0228659784.USD","06160","LU0244354667.USD","LU0650527681.SGD","LU1303224171.USD","LU2097828474.EUR","01477","LU1831875114.USD","LU2488822045.USD","LU0326950275.SGD","BK1515","LU2097828805.USD","BK1161","01801","BK1500","LU1719994722.HKD","01177","KCAI","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106499378","title":"异动解读｜科伦博泰生物盘中上涨3.16%，12亿元结构性存款认购落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1106499378","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106499378?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:47","pubTimestamp":1793843257,"startTime":"0","endTime":"0","summary":"11月5日，科伦博泰生物盘中上涨3.16%，报469.2港元，成交额1.21亿港元。消息面上，公司日前公告分别认购5亿元浙商银行及7亿元中国银行结构性存款，合计12亿元，构成两笔须予披露交易。公告显示，上述资金均来自集团闲置自有资金，未动用公开发行或配股所得款项，产品属性为保本浮动收益型、具中短期特征。公司表示，此举旨在提升闲置资金使用效率，也反映其账上资金相对充裕。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科伦博泰生物上涨，12亿结构性存款落地","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680205810","title":"科伦博泰生物(06990.HK)认购5亿元浙商银行结构性存款及7亿元中国银行结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2680205810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680205810?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:42","pubTimestamp":1793792528,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1048588211.SGD","LU0235996351.USD","LU1961090484.USD","LU0307460666.USD","BK1161","03988","LU1813983027.USD","SG9999006597.SGD","LU2097828805.USD","LU1282651048.USD","LU0588546209.SGD","LU0651946864.USD","LU1051769294.HKD","LU1720050803.USD","LU2097828474.EUR","LU2097828714.EUR","BK1521","HK0000286598.CNH","LU1497734951.SGD","LU2097828631.EUR","03143","LU1224444064.USD","LU1515016050.SGD","IE00B19Z5X02.USD","LU1282651121.HKD","LU2039709279.SGD","LU1634259557.SGD","LU1328277881.USD","LU0196878994.USD","LU0314109678.HKD","BK1560","IE00BQJZWZ67.USD","LU0651947912.USD","LU1522347837.USD","LU2097828557.USD","SG9999004220.SGD","LU1051768304.USD","02016","LU1497733557.USD","LU1794554557.SGD","SG9999001093.SGD","LU1634259391.SGD","LU0348805143.USD","LU2399975544.HKD","06990","IE00BWDBJ730.SGD","LU1497733631.SGD","LU0293314216.USD","BK1231","LU0072462343.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159523874","title":"科伦博泰生物(06990)认购总额12亿元银行结构性存款 涉两笔须予披露交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1159523874","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159523874?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:41","pubTimestamp":1793792506,"startTime":"0","endTime":"0","summary":"2026年11月4日，科伦博泰生物医药股份有限公司公告称，公司当日分别与浙商银行及中国银行签署新的结构性存款协议，合计认购金额12亿元，均使用集团闲置自有资金。公司指出，本次认购的结构性存款均为保本浮动收益型，具备中短期特征及预期回报水平，旨在提高闲置自有资金的使用效率；相关资金未动用任何公开发行或配股所得款项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166734834","title":"科伦博泰生物更新2026年10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1166734834","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166734834?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:38","pubTimestamp":1793781529,"startTime":"0","endTime":"0","summary":"科伦博泰生物于2026年11月4日披露的月报显示，截至2026年10月31日，公司已发行股本及注册股本均保持不变。H股已发行数量为176,822,257股，内资股已发行数量为62,201,712股，期末注册股本合计为人民币239,023,969元，整体结构与上月一致。关于2025年股份激励计划，虽有435,064份限制性股票单位计划授予，但10月内并未实际新增发行股份，股本规模未受影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519700","title":"CXO板块逆市走强 百济神州（06160）涨5.14%、凯莱英（06821）涨4.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519700","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680519700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:34","pubTimestamp":1793759693,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块逆市走强，百济神州 涨5.14%，凯莱英涨4.19%，药明康德涨3.92%，药明生物涨3.58%，科伦博泰生物涨2.89%，药明合联涨2.44%，和铂医药-B涨1.76%，康龙化成涨1.46%，和黄医药涨1.17%。湘财证券表示，CXO龙头药明康德三季报超预期、指引上修，印证CXO由周期修复转向CRDMO结构性重估。维持药品行业“买入”评级，建议关注创新化学制剂及创新药产业链上游CXO公司。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995187","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","LU0051755006.USD","LU1720050803.USD","688235","002821","02142","LU0348766576.USD","BK1574","LU0823426480.USD","06821","00013","LU0502904849.HKD","LU0463099449.HKD","LU0326950275.SGD","LU0828237510.HKD","LU0516422440.USD","03759","LU0128522744.USD","LU0455707207.USD","LU0043850808.USD","LU2045819591.USD","LU0456827905.SGD","LU0588546209.SGD","KURE","02359","LU0229945570.USD","LU0327786744.USD","02269","06990","LU0128526141.USD","02268","BK1141","LU3063872942.SGD","SG9999002463.SGD","LU0072913022.USD","WX","LU0359202008.SGD","LU0501845795.SGD","LU2476274308.USD","LU0320764243.SGD","ONC","LU2476274720.SGD","LU1719994722.HKD","LU0516423091.SGD","LU1242518857.USD","BK0132","06160","CXO","SG9999002562.SGD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136692170","title":"异动解读｜科伦博泰生物盘中上涨3.59%，创新药临床与申报进展持续提供支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1136692170","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136692170?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:09","pubTimestamp":1793758185,"startTime":"0","endTime":"0","summary":"11月4日，科伦博泰生物盘中上涨3.59%，报416.0港元，成交额7189.14万港元。消息面上，公司核心产品芦康沙妥珠单抗近期披露多项积极进展，成为股价波动的重要支撑。具体来看，公司此前公布，sac-TMT在ESMO大会亮相三项III期研究，其中肺癌研究显示PFS及OS获益；同时，其联合帕博利珠单抗用于一线PD-L1阴性非鳞状NSCLC的新增适应症上市申请已获受理。多家机构随后维持买入或跑赢大市评级，目标价区间约520至678港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科伦博泰生物上涨，创新药临床进展持续催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190620653","title":"异动解读｜科伦博泰生物盘中下跌6.11%，实控人连续减持压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190620653","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190620653?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:44","pubTimestamp":1793670298,"startTime":"0","endTime":"0","summary":"11月3日，科伦博泰生物盘中下跌6.11%，报399.4港元，成交额6588.17万港元。消息面上，公司实控人刘革新于10月26日至10月30日连续在场内减持，最新一次于10月30日以每股430.36港元卖出5.72万股，套现约2461.66万港元，减持后好仓比例降至48.65%。此前其还分别于10月29日、10月28日、10月27日及10月26日持续出售股份，持股比例由48.96%逐步降至48.65%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科伦博泰生物下跌，实控人连续减持施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995153.HKD","02596","02268","06078","BK0028","01093","LU1794554557.SGD","LU0828237510.HKD","09939","LU0607220059.USD","02269","02273","01952","06160","LU0979878070.USD","02162","IE00B031HY20.USD","LU2488822045.USD","LU0348825331.USD","01177","03759","KCE","LU0039217434.USD","LU1064131003.USD","LU1969619763.USD","03692","LU0348766576.USD","LU0708995583.HKD","01548","09996","06030","06996","LU0455707207.USD","09966","LU0823426480.USD","01951","HK0000320264.USD","KURE","LU0588546209.SGD","06990","01530","09926","02096","00013","159938","600030","LU1226287529.USD","06821","01801","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680038783","title":"天风 · 11月金股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680038783","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680038783?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:50","pubTimestamp":1793577000,"startTime":"0","endTime":"0","summary":"资料来源：WIND，天风证券研究所静待美国中期选举——港股策略周观察1、美国中期选举将于11月3日举行。截至10月17日当周，首次申请失业救济人数减少6,000人至19.4万人，为7月18日当周以来最低，低于前一周的20万人。截至2026Q3，投资者结构中公募基金占比超50%的转债共102只，较26Q2末增加7只。2026Q3，40只转债基金合计份额环比上涨3.37%，可转债市值占基金资产净值比例上涨0.90pct至92.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649155161&idx=1&sn=88bc58d00e363a24b85fda536d98e590&chksm=8294085374957795c28a4e0e2409914c12fa9f7c2e2fd813adbd7f0c5715dbc54e34c05d5db6&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["ROM","TEK","NVD3.UK","NVDG","AGOX","CHAT","NVII","NVDY","USXF","DIPS","NVD","SOXX","SMH","00268","SMHX","NVDU","NVDL","CLSE","FAI","NVD2.UK","NVDW","NVDS","07388","09388","SNPE","AIFD","AIPI","NVDD","LFGY","NULC","NVDS.UK","06990","ARTY","SOXY","CHPX","09788","SHOC","01797","00667","NVDX","FDTX","SOXQ","06055","NVDQ","2NVD.UK","GAMR","07788","NVDB","THMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144460296","title":"科伦博泰生物：刘革新减持，好仓比例降至48.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144460296","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144460296?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:41","pubTimestamp":1793353291,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月28日在联交所场内以每股均价441.7港元卖出科伦博泰生物股份11.17万股，涉资约4933.79万港元，属场内主动交易，即在二级市场直接买卖股份。刘革新此次减持前持有科伦博泰生物好仓8627.82万，占比48.79%；减持后持股量为8616.65万，好仓比例降至48.73%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143211435","title":"科伦博泰生物：刘革新减持，好仓比例降至48.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143211435","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143211435?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:33","pubTimestamp":1793352833,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月27日在联交所场内以每股均价456.43港元卖出科伦博泰生物（06990）股份11.88万股，涉资约5422.39万港元。该笔属场内主动交易，即在二级市场直接买卖股份。刘革新此次减持前持有科伦博泰生物好仓8639.70万，占比48.86%；减持后持股量为8627.82万，好仓比例降至48.79%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117532741","title":"科伦博泰生物：刘革新减持，好仓比例降至48.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117532741","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117532741?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:33","pubTimestamp":1793352816,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月26日在联交所场内以每股均价478.57港元卖出科伦博泰生物（06990）股份16.64万股，涉资约7963.40万港元，属场内主动交易，即在二级市场直接买卖股份。披露补充称，其控制的科伦博泰员工持股平台科伦汇德、科伦汇能、科伦汇智、科伦汇才于当日在二级市场出售科伦博泰生物股票，合计出售数量不超过该股当日成交量的10%。刘革新此次减持前持有科伦博泰生物好仓8656.34万股，占比48.96%；减持后持股量为8639.70万股，好仓比例降至48.86%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147443349","title":"科伦博泰生物：刘革新减持，好仓比例降至48.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147443349","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147443349?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:21","pubTimestamp":1793352068,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月30日在联交所场内以每股均价430.36港元卖出科伦博泰生物（06990）股份5.72万股，涉资约2461.66万港元，属场内主动交易，即在二级市场直接买卖股份。刘革新此次减持前持有科伦博泰生物好仓8608.37万，占比48.68%；减持后持股量为8602.65万，好仓比例降至48.65%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192195201","title":"科伦博泰生物：刘革新减持，好仓比例降至48.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192195201","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192195201?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:14","pubTimestamp":1793351680,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月29日在联交所场内以每股均价441.9200港元卖出科伦博泰生物（06990）股份8.28万股，涉资约3659.10万港元。该笔为场内主动交易，属二级市场直接买卖。刘革新此次减持前持有科伦博泰生物好仓8616.65万，占比48.73%；减持后持股量为8608.37万，好仓比例降至48.68%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197327212","title":"异动解读｜科伦博泰生物盘中上涨3.37%，sac-TMT三项III期研究入选LBA提振预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1197327212","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197327212?lang=zh_cn&edition=full","pubTime":"2026-10-29 11:07","pubTimestamp":1793243253,"startTime":"0","endTime":"0","summary":"10月29日，科伦博泰生物盘中上涨3.37%，报448.2港元，成交额1.71亿港元。消息面上，机构最新维持公司买入评级，并指出芦康沙妥珠单抗sac-TMT三项III期研究亮相ESMO大会且入选最新突破性摘要，覆盖肺癌及子宫内膜癌。其中，OptiTROP-Lung06支持其联合帕博利珠单抗用于一线PD-L1阴性非鳞状NSCLC的新适应症申请已获受理；机构认为相关研究补充了PD-L1阴性人群III期证据，并首次在全球III期验证TROP2 ADC带来OS及PFS双重获益，有望为海外注册及商业化提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科伦博泰生物上涨，sac-TMT研究入选LBA","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.1549},{"period":"1month","weight":0.0432},{"period":"3month","weight":-0.1224},{"period":"6month","weight":0.0667},{"period":"1year","weight":0.1219},{"period":"ytd","weight":0.1826}],"compareEarnings":[{"period":"1week","weight":0.0438},{"period":"1month","weight":0.0143},{"period":"3month","weight":-0.0347},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0785},{"period":"ytd","weight":-0.0419}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.042518},{"month":9,"riseRate":0.75,"avgChangeRate":0.058448},{"month":10,"riseRate":0.25,"avgChangeRate":-0.058097},{"month":11,"riseRate":1,"avgChangeRate":0.077171},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}